Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Biomarin Pharmaceutical Inc (BMRN)  
$90.87 0.64 (0.7%) as of 4:30 Tue 4/16


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 188,370,000
Market Cap: 17.12(B)
Last Volume: 1,235,787 Avg Vol: 1,397,134
52 Week Range: $76.22 - $100.3
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    NASDAQ BIOTECHNOLOGY     NASDAQ COMPOSITE
    NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  811
Guru Rank Value     : 0.9
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 3,625
Total Buy Value $0 $0 $0 $314,469
Total People Bought 0 0 0 1
Total Buy Transactions 0 0 0 1
Total Shares Sold 139,229 182,993 316,353 658,922
Total Sell Value $12,316,080 $16,513,389 $28,948,007 $62,013,572
Total People Sold 5 5 6 8
Total Sell Transactions 11 15 24 58
End Date 2024-01-18 2023-10-17 2023-04-18 2022-04-18

   
Records found: 1283
  Page 5 of 52  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-10 4 AS $70.00 $350,000 I/I (5,000) 50,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-10 4 OE $12.99 $64,950 I/I 5,000 55,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-06 4 AS $67.40 $674,096 I/I (10,000) 50,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-06 4 OE $12.99 $129,900 I/I 10,000 60,740     -
   Fuchs Henry J EVP, Chief Medical Officer   •       –      –    2014-01-02 4 AS $68.97 $63,172 D/D (916) 42,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-02 4 AS $68.90 $344,483 I/I (5,000) 50,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2014-01-02 4 OE $12.99 $64,950 I/I 5,000 55,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-12-24 4 AS $68.71 $687,143 I/I (10,000) 50,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-12-24 4 A $12.99 $129,900 I/I 10,000 60,740     -
   Grey Michael G Director   –       •      –    2013-12-11 4 S $69.66 $2,089,680 D/D (30,000) 23,050     -
   Grey Michael G Director   –       •      –    2013-12-11 4 OE $17.33 $651,300 D/D 30,000 53,050     -
   Lewis Alan Director   –       •      –    2013-12-09 4 S $69.91 $1,572,982 D/D (22,500) 19,300     -
   Lewis Alan Director   –       •      –    2013-12-09 4 OE $26.49 $686,775 D/D 22,500 41,800     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-12-09 4 S $69.55 $906,010 D/D (13,026) 14,880     -
   Ajer Jeffrey Robert SVP, Chief Commercial Of   •       –      –    2013-12-09 4 OE $14.39 $253,183 D/D 13,026 27,906     -
   Lawlis V Bryan Director   –       •      –    2013-12-09 4 S $69.76 $202,301 D/D (2,900) 11,400     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-12-05 4 AS $69.70 $348,485 I/I (5,000) 50,740     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-12-05 4 A $12.99 $64,950 I/I 5,000 55,740     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-12-02 4 AS $70.14 $631,273 D/D (9,000) 37,950     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-12-02 4 OE $39.06 $351,540 D/D 9,000 46,950     -
   Spiegelman Daniel K EVP, Chief Financial Officer   •       –      –    2013-11-20 4 A $65.89 $527 D/D 8 68,760     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-11-14 4 OE $12.99 $64,950 I/I 5,000 50,740     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-11-13 5 GA $0.00 $0 I/I 92 11,047     -
   Baffi Robert EVP, Technical Operations   •       –      –    2013-11-13 5 GD $0.00 $0 D/D 92 60,350     -
   Bienaime Jean Jacques Chief Executive Officer   •       •      –    2013-11-05 4 AS $62.36 $311,779 I/I (5,000) 45,740     -
  1283 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 5 of 52
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us